Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)

Blood (2017) 130 (Supplement 1): 322.

https://doi.org/10.1182/blood.V130.Suppl_1.322.322

Published: 2017

Journal Articles

The Efficacy and Safety of Continued Hydroxyurea Therapy Versus Switching to Ruxolitinib in Patients with Polycythemia Vera: A Randomized, Double-Blind, Double-Dummy, Symptom Study (RELIEF)

Ruben Mesa, MD, Alessandro M. Vannucchi, MD, Abdulraheem Yacoub, MD MB, Pierre Zachee, MD PhD, Mamta Garg, MD FRCP, FRCPath, Roger Lyons, MD, Silwan Chedid, MD, Steffen Koschmieder, MD, Ciro Rinaldi, MD PhD, Jennifer Byrne, MB, ChB, PhD FRCP, FRCPath, Yasmin Hasan, MD, Francesco Passamonti, MD, Srdan Verstovsek, MD PhD, Deborah Hunter, PhD, Mark M Jones, MD, Shui He, PhD, Alex Morozov, MD PhD, Bruno Martino, MD

Blood (2014) 124 (21): 3168.

https://doi.org/10.1182/blood.V124.21.3168.3168

Published: 2014

Journal Articles

Clinical Benefit of Ruxolitinib Treatment after Crossover from Best Available Therapy in Patients with Polycythemia Vera: Analysis of the RESPONSE Trial

Jean-Jacques Kiladjian, MD PhD, Alessandro M. Vannucchi, MD, Martin Griesshammer, MD, Tamas Masszi, MD PhD, Simon Durrant, MD, Francesco Passamonti, MD, Claire N Harrison, DM, FRCP, FRCPath, Fabrizio Pane, MD, Pierre Zachee, MD PhD, Ruben Mesa, MD, Mark M Jones, MD, Shui He, PhD, Jingjin Li, PhD, Dany Habr, MD, Srdan Verstovsek, MD PhD

Blood (2014) 124 (21): 3181.

https://doi.org/10.1182/blood.V124.21.3181.3181

Published: 2014

Journal Articles

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Following Fludarabine Plus 2 Gy TBI or ATG Plus 8 Gy TLI: A Phase II Randomized Study from the Belgian Hematological Society

Yves Beguin, MD PhD, Pierre Zachee, MD PhD, Johan Maertens, MD PhD, Tessa Kerre, MD PhD, Aurelie Ory, Laurence Seidel, Carlos Graux, MD PhD, Philippe Lewalle, MD PhD, Michel Van Gelder, PhD MD, Koen Theunissen, Evelyne Willems, MD PhD, Marie-Paule Emonds, Ann De Becker, Frederic Baron

Blood (2014) 124 (21): 542.

https://doi.org/10.1182/blood.V124.21.542.542

Published: 2014

Journal Articles

Subsequent Hematopoietic Stem Cell Transplantation in Belinostat-Treated Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)

Andrei R. Shustov, MD, Haifa Kathrin Al-Ali, MD, Gerald Wulf, MD, Pamela Hsu, Mi Rim Choi, Lee F Allen, Otto J Visser, MD, Pierre Zachee, MD PhD, Steven M. Horwitz, MD

Blood (2014) 124 (21): 5438.

https://doi.org/10.1182/blood.V124.21.5438.5438

Published: 2014

Journal Articles

Changes in Quality of Life and Disease-Related Symptoms in Patients with Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results

Ruben Mesa, MD, Srdan Verstovsek, MD PhD, Jean-Jacques Kiladjian, MD PhD, Martin Griesshammer, MD, Tamas Masszi, MD PhD, Simon Durrant, MD, Francesco Passamonti, MD, Claire N. Harrison, DM, FRCP, FRCPath, Fabrizio Pane, MD, Pierre Zachee, MD PhD, Shui He, PhD, Mark M Jones, MD, Shreekant Parasuraman, PhD, Jingjin Li, PhD, Isabelle Côté, MD, Dany Habr, MD, Alessandro M. Vannucchi, MD

Blood (2014) 124 (21): 709.

https://doi.org/10.1182/blood.V124.21.709.709

Published: 2014

Journal Articles

Autologous Stem Cell Transplantation (ASCT) for the Treatment of Patients with Waldenstrom’s Macroglobulinemia / Lymphoplasmacytic Lymphoma (WM/LPL). a Risk Factor Analysis By the European Society for Blood and Marrow Transplantation (EBMT) Lymphoma Working Party

Charalampia Kyriakou, MD PhD Consultant Haematologist, Ariane Boumendil, Herve Finel, Jean-Paul Vernant, Jan J. Cornelissen, MD PhD, Catherine Thieblemont, MD PhD, Patrice Chevallier, MD PhD, Rose-Marie Hamladji, Ghulam J Mufti, FRCP, FRCPath, MD, Patrizio Mazza, Pierre Zachee, MD PhD, Dietger Niederwieser, MD, Anna Sureda, Silvia Montoto, MD, Peter Dreger, MD

Blood (2014) 124 (21): 678.

https://doi.org/10.1182/blood.V124.21.678.678

Published: 2014

Journal Articles

R-DHAP Immunochemotherapy Is An Effective Remission-Induction Treatment For CLL Patients With Fludarabine Refractory Disease With Or Without Deletion 17p, Enabling The Majority To Proceed To Allogeneic Stem Cell Transplantation

Michel Van Gelder, PhD, MD, Wendim Ghidey, Martine ED Chamuleau, MD, Jan Cornelissen, MD, PhD, Eefke J Petersen, MD PhD, Simon M. G. J. Daenen, Pierre Zachee, MD, PhD, Mels Hoogendoorn, MD, PhD, Aart Beker, MD, Gert Jan Timmers, MD, PhD, Arnon P. Kater, MD PhD, Marinus H.J. Van Oers, MD, PhD

Blood (2013) 122 (21): 2883.

https://doi.org/10.1182/blood.V122.21.2883.2883

Published: 2013

Journal Articles

Baseline Characteristics and Symptom Burden in RESPONSE: A Randomized, Open-Label, Phase 3 Study of Ruxolitinib In Polycythemia Vera Patients Resistant to or Intolerant of Hydroxyurea

Alessandro M. Vannucchi, MD, Jean-Jacques Kiladjian, MD, PhD, Martin Griesshammer, Prof. Dr. med., Tamás Masszi, MD, PhD, Simon Durrant, MBBS, FRCP, FRCPath, Pierre Zachee, MD, PhD, Fabrizio Pane, MD, Claire N Harrison, DM, FRCP, FRCPath, Shui He, PhD, Lance Leopold, MD, Jingjin Li, Ulrich Pirron, PhD, Tomasz Lawniczek, MD, PhD, Srdan Verstovsek, MD, PhD

Blood (2013) 122 (21): 4071.

https://doi.org/10.1182/blood.V122.21.4071.4071

Published: 2013

Journal Articles

CHR-2845, a Monocyte/Macrophage Targeted Histone Deacetylase Inhibitor In a First In Man Clinical Trial In Subjects with Advanced Haematological Malignancies

Gert Ossenkoppele, MD, PhD, Bob Lowenberg, MD, PhD, Pierre Zachee, MD, PhD, Norbert Vey, Dimitri Breems, MD, PhD, Arjan A. Van de Loosdrecht, MD, PhD, Phillip Debnam, PhD, Lindsey Needham, PhD, Lindsay Bawden, PhD, Leon Hooftman, MD

Blood (2010) 116 (21): 3279.

https://doi.org/10.1182/blood.V116.21.3279.3279

Published: 2010

Journal Articles

Autologous Stem Cell Transplantation Followed by Reduced Intensity Allogeneic Stem Cell Transplantation (Tandem Transplantation) as Treatment for Advanced Resistant Hodgkin’s Lymphoma Patients. A Retrospective Analysis of the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT).

Ivan Alvarez, MD, Carme Canals, MD, Goli Taghipour, Angelo M. Carella, MD, PhD, Yves Beguin, MD, PhD, Didier Blaise, MD, PhD, Danielle Lazzlo, MD, PhD, Bernardino Aillone, MD, PhD, Jean H. Bourhis, MD, PhD, Lucca Castagna, MD, PhD, Paolo Corradini, MD, PhD, Paolo Iacopino, MD, PhD, Giuseppe Milone, MD, PhD, Pedro Pimentel, MD, PhD, Nigel H. Russell, MD, PhD, Pierre Zachee, MD, PhD, Anna Sureda, MD, PhD

Blood (2006) 108 (11): 3044.

https://doi.org/10.1182/blood.V108.11.3044.3044

Published: 2006

NARROW

Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)

The Efficacy and Safety of Continued Hydroxyurea Therapy Versus Switching to Ruxolitinib in Patients with Polycythemia Vera: A Randomized, Double-Blind, Double-Dummy, Symptom Study (RELIEF)

Clinical Benefit of Ruxolitinib Treatment after Crossover from Best Available Therapy in Patients with Polycythemia Vera: Analysis of the RESPONSE Trial

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Following Fludarabine Plus 2 Gy TBI or ATG Plus 8 Gy TLI: A Phase II Randomized Study from the Belgian Hematological Society

Subsequent Hematopoietic Stem Cell Transplantation in Belinostat-Treated Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)

Changes in Quality of Life and Disease-Related Symptoms in Patients with Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results

Autologous Stem Cell Transplantation (ASCT) for the Treatment of Patients with Waldenstrom’s Macroglobulinemia / Lymphoplasmacytic Lymphoma (WM/LPL). a Risk Factor Analysis By the European Society for Blood and Marrow Transplantation (EBMT) Lymphoma Working Party

R-DHAP Immunochemotherapy Is An Effective Remission-Induction Treatment For CLL Patients With Fludarabine Refractory Disease With Or Without Deletion 17p, Enabling The Majority To Proceed To Allogeneic Stem Cell Transplantation

Baseline Characteristics and Symptom Burden in RESPONSE: A Randomized, Open-Label, Phase 3 Study of Ruxolitinib In Polycythemia Vera Patients Resistant to or Intolerant of Hydroxyurea

CHR-2845, a Monocyte/Macrophage Targeted Histone Deacetylase Inhibitor In a First In Man Clinical Trial In Subjects with Advanced Haematological Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only